+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant



Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant



Leukemia and Lymphoma 51(9): 1705-1710



Invasive aspergillosis (IA) is a major cause of morbidity in patients with hematological malignancies, and a major impediment to the success of allogeneic stem cell transplant (allo-SCT). The aim of this single-center retrospective study was to determine the impact of pre-transplant IA on the outcome of allo-SCT after reduced-intensity conditioning (RIC). Twenty-eight cases of proven or probable IA were diagnosed prior to RIC allo-SCT at the Paoli-Calmettes Institute Cancer Center between January 2000 and January 2008. These cases were identified among 360 patients undergoing allo-SCT. IA was defined according to EORTC criteria. Patients had predominantly (82%) acute myeloid leukemia, were diagnosed with IA at a median of 8 months (range, 1-16) pre-transplant, and received antifungal therapy for a median of 5 months (range, 1-13). IA therapy included: voriconazole (71%); single-agent itraconazole (14%); and a combination of agents (14%). Secondary prophylaxis against aspergillosis was maintained during conditioning and post-transplant in 89% of patients. After transplant, only three patients (11%) had reactivation of their IA and one patient developed disseminated fusariosis. The latter four patients experienced severe acute GVHD treated with high-dose corticosteroids. None of these patients died of IA. Eighteen patients (64%) are still alive, with a median follow-up of 23.5 months (range, 12.6-48.5). Overall survival at 2 years was 59% (95% CI, 43-83%). These data suggest that patients with adequately controlled IA can tolerate RIC allo-SCT without significant post-transplant complications.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053722614

Download citation: RISBibTeXText

PMID: 20629522

DOI: 10.3109/10428194.2010.500433


Related references

No Evidence of Impact of Maraviroc on Outcome after Allogeneic Hematopoietic Stem Cell Transplant with Reduced Intensity Conditioning (RIC). Biology of Blood and Marrow Transplantation 22(3): S396-S397, 2016

Reduced intensity conditioning regimens: Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Bone Marrow Transplantation 30(2): 63-68, 2002

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with a History of Prior Invasive Aspergillosis Outcomes and Risks for Post-Transplant Invasive Aspergillosis. Blood 100(11): Abstract No 2463, 2002

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 108(9): 2928-2936, 2006

Impact of ATG Dose on the Outcome of Patients Undergoing Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Acta Haematologica 136(4): 193-200, 2016

Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagnostic Microbiology and Infectious Disease 55(3): 209-212, 2006

Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leukemia Research 34(6): 723-727, 2010

Reduced-intensity conditioning prior to allogeneic hematopoietic stem Cell transplantation in patients over 6 years A report from the SFGM-TC. 2011

Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. Leukemia and Lymphoma 59(4): 837-843, 2018

Low transplant-related mortality after second allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in adult patients who failed a prior autologous transplant. Blood 98(11 Part 1): 420a, 2001

Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 38(2): 101-109, 2006

Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. International Journal of Hematology 103(4): 444-452, 2016

Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biology of Blood and Marrow Transplantation 14(6): 702-708, 2008

Reduced intensity conditioning allogeneic hematopoietic stem cell transplant could be beneficial to angioimmunoblastic T-cell lymphoma patients with hemophagocytic lymphohistiocytosis. Annals of Hematology 91(5): 805-807, 2012

Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). Biology of Blood and Marrow Transplantation 22(3): S316-S317, 2016